'Not scientifically supportable:' Inside FDA's refusal to face US generic drug crisis

The report names its authors and includes interviews with an outside expert and an agency response, supporting some transparency. The publisher is a local outlet, but the available information does not establish its corrections practices or broader reporting record.

• ▸Source type — WPDE is presented as a local news publisher; no more specific source classification is available.
• ▸Author attribution — Three reporters are named.
• ▸Editorial standards — The report includes attributed interviews and the FDA's written response, though it is strongly framed around criticism of the agency.
• ▸Transparency — The article describes the reporters' interview request and the agency's response, but offers limited information about the outlet's policies.

The report includes a named expert, congressional statements and the FDA's response, and describes the agency's opportunity to comment. The FDA's position is represented mainly through a written statement, while the article gives substantially more space to critics and provides limited independent evidence or competing context.

The report includes the FDA's stated position and its response to the reporters, but most of the detailed discussion comes from critics of the agency. The FDA's direct response to the specific questions was unavailable by deadline, leaving the article weighted toward one perspective.

• ▸Counterarguments presented — The FDA's general position is quoted, but the report says it did not directly answer the reporters' questions.
• ▸Source diversity — The report includes a physician-researcher, two lawmakers and an agency statement, but detailed evidence and argument chiefly come from critics.
• ▸Omitted context — The report gives limited context supporting the FDA's position or explaining the agency's oversight practices.

The report is sharply critical of the FDA's handling of generic-drug oversight, but that framing does not establish a discernible left-right political lean. Its focus is regulatory oversight and drug safety rather than partisan politics.

• ▸Language tone — The framing emphasizes criticism of the FDA, but does not use clear partisan language.
• ▸Source selection — Most interview material comes from critics of the FDA, while the agency's position is included in a written statement.
• ▸Framing — The report foregrounds a dispute over regulatory oversight without a clear partisan frame.